Plasma biomarkers for brain injury in extracorporeal membrane oxygenation

키워드

참고문헌 (62)

1. Lang NW, "Survival rate and outcome of extracorporeal life support(ECLS)for treatment of acute cardiorespiratory failure in trauma patients", Sci Rep, 9, pp.12902~ (2019)
2. Migdady I, "Brain injury and neurologic outcome in patients undergoing extracorporeal cardiopulmonary resuscitation : a systematic review and meta-analysis", Crit Care Med, 48, pp.e611~9 (2020)
3. Cho SM, "Noninvasive neurological monitoring in extracorporeal membrane oxygenation", ASAIO J, 66, pp.388~393 (2020)
4. Ong CS, "Neuromonitoring detects brain injury in patients receiving extracorporeal membrane oxygenation support", J Thorac Cardiovasc Surg, 165, pp.2104~2110 (2023)
5. Cho SM, "Assessing the SAfety and FEasibility of bedside portable low-field brain Magnetic Resonance Imaging in patients on ECMO(SAFE-MRI ECMO study) : study protocol and first case series experience", Crit Care, 26, pp.119~ (2022)
6. Kim YJ, "Different neuroprognostication thresholds of neuron-specific enolase in shockable and non-shockable out-of-hospital cardiac arrest : a prospective multicenter observational study in Korea(the KORHN-PRO registry)", Crit Care, 27, pp.313~ (2023)
7. Gul SS, "Prognostic utility of neuroinjury biomarkers in post out-of-hospital cardiac arrest(OHCA)patient management", Med Hypotheses, 105, pp.34~47 (2017)
8. Lee D, "Neuron-specific enolase level as a predictor of neurological outcome in near-hanging patients : a retrospective multicenter study", PLoS One, 16, pp.e0246898~ (2021)
9. Bembea MM, "Plasma biomarkers of brain injury as diagnostic tools and outcome predictors after extracorporeal membrane oxygenation", Crit Care Med, 43, pp.2202~2211 (2015)
10. Floerchinger B, "NSE serum levels in extracorporeal life support patients : relevance for neurological outcome?", Resuscitation, 121, pp.166~171 (2017)
11. Ramont L, "Effects of hemolysis and storage condition on neuron-specific enolase(NSE)in cerebrospinal fluid and serum : implications in clinical practice", Clin Chem Lab Med, 43, pp.1215~1217 (2005)
12. Hol EM, "Glial fibrillary acidic protein(GFAP)and the astrocyte intermediate filament system in diseases of the central nervous system", Curr Opin Cell Biol, 32, pp.121~130 (2015)
13. Niebrój-Dobosz I, "Immunochemical analysis of some proteins in cerebrospinal fluid and serum of patients with ischemic strokes", Folia Neuropathol, 32, pp.129~137 (1994)
14. Herrmann M, "Release of glial tissue-specific proteins after acute stroke : a comparative analysis of serum concentrations of protein S-100B and glial fibrillary acidic protein", Stroke, 31, pp.2670~2677 (2000)
15. Dvorak F, "Characterisation of the diagnostic window of serum glial fibrillary acidic protein for the differentiation of intracerebral haemorrhage and ischaemic stroke", Cerebrovasc Dis, 27, pp.37~41 (2009)
16. Kaneko T, "Serum glial fibrillary acidic protein as a predictive biomarker of neurological outcome after cardiac arrest", Resuscitation, 80, pp.790~794 (2009)
17. Hayashida H, "Comparison of the predictability of neurological outcome by serum procalcitonin and glial fibrillary acidic protein in postcardiac-arrest patients", Neurocrit Care, 12, pp.252~257 (2010)
18. Wiesmann M, "Outcome prediction in traumatic brain injury : comparison of neurological status, CT findings, and blood levels of S100B and GFAP", Acta Neurol Scand, 121, pp.178~185 (2010)
19. Pelinka LE, "Glial fibrillary acidic protein in serum after traumatic brain injury and multiple trauma", J Trauma, 57, pp.1006~1012 (2004)
20. Pelinka LE, "GFAP versus S100B in serum after traumatic brain injury : relationship to brain damage and outcome", J Neurotrauma, 21, pp.1553~1561 (2004)
21. Nylén K, "Increased serum-GFAP in patients with severe traumatic brain injury is related to outcome", J Neurol Sci, 240, pp.85~91 (2006)
22. Fraser DD, "Severe traumatic brain injury in children elevates glial fibrillary acidic protein in cerebrospinal fluid and serum", Pediatr Crit Care Med, 12, pp.319~324 (2011)
23. Amalia L, "Glial fibrillary acidic protein(GFAP) : neuroinflammation biomarker in acute ischemic stroke", J Inflamm Res, 14, pp.7501~7506 (2021)
24. "Brain injury plasma biomarkers in patients on VA-ECMO: a pilot prospective observational study" (2023)[URL]
25. Avila J, "Role of tau protein in both physiological and pathological conditions", Physiol Rev, 84, pp.361~384 (2004)
26. Gao Y, "Tau in Alzheimer’s disease : mechanisms and therapeutic strategies", Curr Alzheimer Res, 15, pp.283~300 (2018)
27. Zuckerman SL, "Chronic traumatic encephalopathy and neurodegeneration in contact sports and American football", J Alzheimers Dis, 66, pp.37~55 (2018)
28. Magnoni S, "Tau elevations in the brain extracellular space correlate with reduced amyloid-β levels and predict adverse clinical outcomes after severe traumatic brain injury", Brain, 135(Pt 4), pp.1268~1280 (2012)
29. De Vos A, "Neurogranin and tau in cerebrospinal fluid and plasma of patients with acute ischemic stroke", BMC Neurol, 17, pp.170~ (2017)
30. Mattsson N, "Serum tau and neurological outcome in cardiac arrest", Ann Neurol, 82, pp.665~675 (2017)
31. Gabbita SP, "Cleaved-tau : a biomarker of neuronal damage after traumatic brain injury", J Neurotrauma, 22, pp.83~94 (2005)
32. Gaetani L, "Neurofilament light chain as a biomarker in neurological disorders", J Neurol Neurosurg Psychiatry, 90, pp.870~881 (2019)
33. Gafson AR, "Neurofilaments : neurobiological foundations for biomarker applications", Brain, 143, pp.1975~1998 (2020)
34. Thebault S, "Blood neurofilament light chain : the neurologist’s troponin?", Biomedicines, 8, pp.523~ (2020)
35. Moseby-Knappe M, "Serum neurofilament light chain for prognosis of outcome after cardiac arrest", JAMA Neurol, 76, pp.64~71 (2019)
36. Wihersaari L, "Neurofilament light compared to neuron-specific enolase as a predictor of unfavourable outcome after out-of-hospital cardiac arrest", Resuscitation, 174, pp.1~8 (2022)
37. Levin H, "Plasma neurofilament light is a predictor of neurological outcome 12 h after cardiac arrest", Crit Care, 27, pp.74~ (2023)
38. Martucci G, "Identification of a circulating miRNA signature to stratify acute respiratory distress syndrome patients", J Pers Med, 11, pp.15~ (2020)
39. Zhang JM, "Cytokines, inflammation, and pain", Int Anesthesiol Clin, 45, pp.27~37 (2007)
40. Datzmann T, "Extracorporeal membrane oxygenation and cytokine adsorption", J Thorac Dis, 10(Suppl 5), pp.S653~60 (2018)
41. Caprarola SD, "Pediatric ECMO : unfavorable outcomes are associated with inflammation and endothelial activation", Pediatr Res, 92, pp.549~556 (2022)
42. Burrell AJC, "The impact of venovenous extracorporeal membrane oxygenation on cytokine levels in patients with severe acute respiratory distress syndrome : a prospective, observational study", Crit Care Resusc, 19(Suppl 1), pp.37~44 (2017)
43. Setiadi H, "Oncostatin M as a biomarker to predict the outcome of VV ECMO supported patients with acute pulmonary failure", J Heart Lung Transplant, 39(4 Supplement), pp.S390~ (2020)
44. Guo S, "Oncostatin M confers neuroprotection against ischemic stroke", J Neurosci, 35, pp.12047~12062 (2015)
45. Knight D, "Encyclopedia of respiratory medicine", pp.254~258 (2006), Academic Press
46. Harrington JS, "Circulating mitochondrial DNA as predictor of mortality in critically ill patients : a systematic review of clinical studies", Chest, 156, pp.1120~1136 (2019)
47. Shimada K, "Oxidized mitochondrial DNA activates the NLRP3 inflammasome during apoptosis", Immunity, 36, pp.401~414 (2012)
48. Nakahira K, "The roles of mitochondrial damage-associated molecular patterns in diseases", Antioxid Redox Signal, 23, pp.1329~1350 (2015)
49. Mao JY, "Plasma mitochondrial DNA levels are associated with acute lung injury and mortality in septic patients", BMC Pulm Med, 21, pp.66~ (2021)
50. Puskarich MA, "Plasma levels of mitochondrial DNA in patients presenting to the emergency department with sepsis", Shock, 38, pp.337~340 (2012)
51. Fan JX, "The hidden link between plasma mitochondrial DNA level and cardiac dysfunction after cardiopulmonary bypass", Research Square (2020)[DOI]
52. Bynum J, "Increased mitochondrial DNA in an ECMO model is associated with loss of platelet function", Blood, 130(Suppl 1), pp.1126~ (2017)
53. Tsai NW, "The value of serial plasma nuclear and mitochondrial DNA levels in patients with acute ischemic stroke", Clin Chim Acta, 412, pp.476~479 (2011)
54. Corcoran RB, "Application of cell-free DNA analysis to cancer treatment", N Engl J Med, 379, pp.1754~1765 (2018)
55. Bustamante A, "Circulating cell-free DNA is a predictor of short-term neurological outcome in stroke patients treated with intravenous thrombolysis", J Circ Biomark, 5, pp.1849454416668791~ (2016)
56. Vajpeyee A, "Clinical usefulness of cell-free DNA as a prognostic marker in acute ischemic stroke", Neurologist, 25, pp.11~13 (2020)
57. Rainer TH, "Prognostic use of circulating plasma nucleic acid concentrations in patients with acute stroke", Clin Chem, 49, pp.562~569 (2003)
58. Wang HC, "The value of serial plasma nuclear and mitochondrial DNA levels in acute spontaneous intra-cerebral haemorrhage", Eur J Neurol, 19, pp.1532~1538 (2012)
59. Hogan SR, "Discovery of lipidome alterations following traumatic brain injury via high-resolution metabolomics", J Proteome Res, 17, pp.2131~2143 (2018)
60. Gier EC, "Lipidome alterations following mild traumatic brain injury in the rat", Metabolites, 12, pp.150~ (2022)
61. Thomas I, "Serum metabolome associated with severity of acute traumatic brain injury", Nat Commun, 13, pp.2545~ (2022)
62. Gusdon AM, "Lysophospholipids are associated with outcomes in hospitalized patients with mild traumatic brain injury", J Neurotrauma (2023)[DOI]